See more : Jiangsu Yangnong Chemical Co., Ltd. (600486.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Orgenesis Inc. (ORGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orgenesis Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Galaxy Gaming, Inc. (GLXZ) Income Statement Analysis – Financial Results
- Starzen Company Limited (8043.T) Income Statement Analysis – Financial Results
- XPO Logistics, Inc. (0M1O.L) Income Statement Analysis – Financial Results
- IDP Education Limited (IEL.AX) Income Statement Analysis – Financial Results
- CIBL, Inc. (CIBY) Income Statement Analysis – Financial Results
Orgenesis Inc. (ORGS)
About Orgenesis Inc.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 530.00K | 36.03M | 35.50M | 7.65M | 33.26M | 18.66M | 10.09M | 6.40M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.26M | 20.44M | 28.16M | 30.62M | 18.12M | 10.70M | 6.81M | 7.66M | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00 |
| Gross Profit | -5.73M | 15.59M | 7.34M | -22.97M | 15.14M | 7.96M | 3.28M | -1.26M | -906.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00 |
| Gross Profit Ratio | -1,080.19% | 43.26% | 20.68% | -300.13% | 45.53% | 42.65% | 32.53% | -19.70% | -30.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.09M | 6.01M | 36.64M | 83.99M | 12.46M | 6.46M | 2.48M | 2.16M | 1.07M | 1.69M | 1.64M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.62M | 16.16M | 15.40M | 19.35M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 0.00 |
| Selling & Marketing | 464.00K | -566.00K | -687.00K | -380.00K | 1.15M | 1.21M | 599.00K | 397.00K | 326.00K | 144.00K | 187.83K | 140.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.62M | 16.16M | 14.71M | 18.97M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 3.00K |
| Other Expenses | 0.00 | 788.00K | -1.33M | 474.00K | 2.04M | -1.02M | 1.63M | 2.12M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Operating Expenses | 45.76M | 22.95M | 50.02M | 103.43M | 39.74M | 22.06M | 14.80M | 10.23M | 6.31M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.00K |
| Cost & Expenses | 52.01M | 43.39M | 50.02M | 103.43M | 57.86M | 32.75M | 21.60M | 17.88M | 10.19M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.50K |
| Interest Income | 0.00 | 1.82M | 943.00K | 1.25M | 498.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.17M | 1.82M | 1.29M | 1.06M | 461.00K | 2.75M | 1.23M | 689.00K | 696.00K | 691.09K | 172.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.56M | 1.98M | 1.86M | 1.44M | 3.81M | 2.62M | 2.60M | 2.92M | 1.99M | 4.55K | 3.26K | 1.41K | 0.00 | 15.00K | 0.00 | 0.00 |
| EBITDA | -60.72M | -8.30M | -15.72M | -94.21M | -18.91M | -12.39M | -9.85M | -9.04M | -2.64M | -4.80M | -5.36M | -5.00M | -72.35K | -6.17K | -25.65K | -3.50K |
| EBITDA Ratio | -11,456.23% | -19.15% | -39.00% | -1,244.08% | -62.73% | -65.47% | -100.96% | -135.77% | -175.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -53.64M | -7.37M | -42.68M | -95.78M | -24.60M | -14.65M | -11.23M | 11.28M | -7.21M | -4.58M | -5.46M | -4.99M | -72.35K | -21.17K | -25.65K | -3.50K |
| Operating Income Ratio | -10,120.00% | -20.45% | -120.22% | -1,251.71% | -73.98% | -78.53% | -111.31% | 176.29% | -242.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.81M | -1.85M | -1.15M | -1.63M | -47.00K | -2.83M | -3.66M | -1.26M | 1.85M | -927.10K | -78.66K | -519.21K | 0.00 | -15.00K | 0.00 | 0.00 |
| Income Before Tax | -64.44M | -11.96M | -17.95M | -96.74M | -25.48M | -17.77M | -13.68M | -10.74M | -5.36M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Income Before Tax Ratio | -12,159.43% | -33.20% | -50.56% | -1,264.19% | -76.61% | -95.24% | -135.56% | -167.91% | -180.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 473.00K | 209.00K | 108.00K | -1.61M | 563.00K | 1.34M | -1.31M | -1.55M | -900.00K | 691.09K | 172.51K | 9.58K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -55.36M | -12.17M | -18.06M | -95.13M | -26.04M | -18.29M | -12.37M | -9.19M | -4.46M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Net Income Ratio | -10,445.47% | -33.78% | -50.87% | -1,243.17% | -78.30% | -98.05% | -122.58% | -143.72% | -150.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.28 | -1.08 | -0.96 | -1.22 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.27 | -1.08 | -0.94 | -1.21 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.68M | 8.52M | 4.65M | 4.51M | 4.20M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
| Weighted Avg Shares Out (Dil) | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.71M | 8.52M | 4.74M | 4.56M | 4.21M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globe
Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial year, Orgenesis (NASDAQ:ORGS) reported $35.5 million in revenue compared to $7.7...
Orgenesis achieves latest milestone in its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid
Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has been reached by completing the placement of an Orgenesis (NASDAQ:ORGS) Mobile Processing...
Wall Street stumbles amid looming interest rate hike worries
12:05pm: US markets trend downward US stocks continued to plummet midday on Tuesday, as investors eyed earnings reports from some major corporates and fretted over looming interest rate rises. At noon, the Dow Jones Industrial Average Index shed 1.4%, or...
Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturing
Orgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (POC) treatment of patients at Johns Hopkins. Construction work is planned...
Orgenesis-Theracell Joint Venture Secures €32M Grant From Greek Government
Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance.
Orgenesis and Theracell JV to receive up to €32M from Greek government to accelerate the rollout of therapies
Orgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.” The global biotech company noted that the designation was awarded by Enterprise Greece, the...
Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy center
Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.
Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript
Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript
Orgenesis reports 425% surge in 3Q revenue as POCare platform gains scale
Orgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform. The global biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs), also...
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call
GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference...
Source: https://incomestatements.info
Category: Stock Reports